Puberty and sperm in men
In six men with a hypothalamic cause, pulsed treatment raised testosterone from 77 to 520 ng/dL within a month. Three made sperm by 43 weeks.2
Peptide Guide · Sexual and reproductive health
Gonadorelin
GnRH, gonadotropin-releasing hormone
It took about a quarter of a million pig brains to find gonadorelin’s ten amino acids. The bigger surprise came later, when the same hormone proved able to switch fertility on or off depending largely on its rhythm.
Free to join · One email when peptide care opens · Most lab results in 3–5 business days
- Studied for
- Restoring LH, FSH and fertility in hypothalamic failure
- Evidence
- Human trials
- Taken as
- As prescribed by a clinician
Gonadorelin, in short
Gonadorelin is the synthetic form of GnRH, the hypothalamic hormone that tells the pituitary to release LH and FSH. Rhythm decides what it does. Given in pulses by pump, it restored puberty, sperm production and ovulation in people with hypothalamic failure, while constant exposure shuts the axis down. Human evidence is solid for those specific conditions and thin for other uses.
Medically reviewed by Robert Lufkin, MD (opens in a new tab)
Chief Medical Officer, Vitals Vault · Updated · 14 sources
Before you consider Gonadorelin
How does Gonadorelin work?
It stands in for the brain’s own signal to the gland that starts the sex hormones.
Signals the pituitary
It tells the pituitary gland to release two hormones. In men with hypothalamic failure, they rose to normal within a week.2
Needs a rhythm
Pulses restored the signal in monkeys. A constant supply did not, and could shut the response down.1
Restarts the chain
Once the signal returns, testosterone rises and sperm production or ovulation can follow, as in trials in men and women.235
Gonadorelin benefits: what it is studied for
Gonadorelin has the strongest human evidence in this group, for specific conditions of hypothalamic failure. All of it is from pulsed delivery under specialist care.
- Human study01
- Human study02
Faster sperm than hCG-based therapy
In 28 men with congenital hypogonadotropic hypogonadism, a gonadorelin pump produced sperm after a median 6 months vs 14 with gonadotropin therapy. It was not randomized.5
- Human study03
Ovulation in hypothalamic amenorrhea
In a trial of 109 women, pulsatile gonadorelin led to ovulation in 91% of those with primary and 96% of those with secondary hypothalamic amenorrhea.3
What the research shows
Human trials- 1 · Cells in a labNot cited
This guide cites no findings at this level.
Shows a mechanism
- 2 · Animals Studied
In monkeys with a disabled hypothalamus, pulsed doses restored hormone release. A constant infusion did not.1
Shows an effect in a body
- 3 · People Studied
In 109 women with hypothalamic amenorrhea, a pulsatile pump led to ovulation in over 90%. Smaller trials in men restored sperm production.325
Shows it works in people
Gonadorelin is the best studied peptide in this guide. The evidence covers pulsed delivery by pump in specific hypothalamic conditions. A 2026 review of peptide strategies for testosterone-therapy suppression found that direct evidence of restoring sperm production or fertility after that suppression remains limited, so the evidence does not carry over to every use people ask about.23457
The full guide to Gonadorelin
240,000 pig brains and a Nobel Prize
Imagine needing about 240,000 pig brains to find a molecule ten amino acids long. That was the scale of the race to isolate the hormone that controls fertility. In 1937, the physiologist Geoffrey Harris had shown that the hypothalamus governs the pituitary, and by the late 1960s two rival labs, led by Andrew Schally and Roger Guillemin, were trying to pin down the chemical messengers involved.
Their first prize was a hormone that controls the thyroid, isolated independently by both labs in 1969 from about 160,000 pig hypothalami. Then they turned to reproduction. In 1971, Schally’s group published the proposed structure of the porcine LH- and FSH-releasing hormone, a chain of ten amino acids, and both labs isolated it independently that year.
The hormone has gone by several names, including LHRH and GnRH, and its synthetic version is gonadorelin. In 1977, Schally and Guillemin shared the Nobel Prize in Physiology or Medicine for this line of work.
Synthetic GnRH reached patients quickly. Schally ran the first clinical trials in Mexico in 1972, and within a decade the hormone family was being used in two opposite ways, one to restore fertility and one to shut down testosterone in prostate cancer. The difference between them came down to rhythm.89
How gonadorelin works: one message, read by its rhythm
GnRH is the hypothalamus’s message to the pituitary. It travels a very short distance, through a small network of blood vessels at the base of the brain, and tells pituitary cells to release LH and FSH. Those hormones then tell the testes or ovaries to make sex hormones and to mature sperm or eggs. Gonadorelin is the same ten-amino-acid message, made in a lab.
The natural signal arrives in bursts. In 1978, Ernst Knobil’s group showed that in rhesus monkeys whose hypothalamus had been disabled, synthetic GnRH given in brief pulses matching the monkeys’ natural rhythm restored pituitary hormone release. The same hormone given as a constant infusion failed to do so.
Switching a responding animal from pulses to a constant supply could also shut the response down, a process the authors called desensitization or down-regulation. They concluded that the effect depended on the pattern of delivery rather than the amount. That finding has shaped how gonadorelin has been used ever since.
As a fertility treatment, gonadorelin therefore needs the rest of the chain intact. It stands in for a silent hypothalamus. If the pituitary cannot respond, even a perfect pulse gets no answer. If the testes or ovaries are damaged, LH and FSH may still rise, but sex hormones and fertility do not follow.12
On or off: one hormone, two opposite drugs
In November 1982, the New England Journal of Medicine published a study in which six men who had never gone through a normal puberty were given GnRH in small pulses from a portable pump. Within a week their LH and FSH reached normal adult levels. Within a month, average testosterone had risen from 77 to 520 ng/dL. Three of them were making sperm by 43 weeks.
That same year, the first study of a GnRH agonist for prostate cancer was published, organized by Schally. These drugs are longer-acting copies of the hormone. Given steadily, it overwhelms the pituitary’s receptors until they stop responding, so LH falls and testosterone falls with it. These analogs went on to transform the management of hormone-driven prostate cancer.
One hormone family, opposite results, and the deciding factor is rhythm. Pulses keep the receptor responsive and the axis running. A constant signal, or a long-acting copy, teaches the pituitary to tune out. The body relies on this distinction all the time, which is why the hypothalamus fires in bursts instead of a steady stream.
For anyone curious about gonadorelin, the pattern of delivery matters as much as the drug. The trials that worked used programmed pumps that copied a natural pulse. Whether occasional injections can do the same job has not been well tested, which makes it a fair question to put to any prescriber.281
Gonadorelin for men: puberty, testosterone and sperm
The 1982 men also showed what a restarted axis feels like. All six noticed spontaneous erections, nocturnal emissions and breast tenderness as their testosterone rose, and testis size increased in four of them. Those are the ordinary signs of puberty, arriving years late.
Later work compared approaches. In a 2019 nonrandomized study from Guangzhou, 28 men with congenital hypogonadotropic hypogonadism and no sperm were treated with either a gonadorelin pump or cyclical hCG and hMG injections. Sperm appeared after a median of 6 months on the pump versus 14 months on gonadotropins, and in 90 versus 83.3 percent of men by two years, a difference that was not statistically significant.
The pump group also had more moderate testosterone levels, while the gonadotropin group tended toward higher testosterone with more acne and breast tenderness. Skin reactions at the pump site were a common side effect, a reminder that the delivery device carries its own burdens alongside the hormone.
A 2024 review put the bigger picture in one number. Both pulsatile GnRH and combined gonadotropin therapy induce sperm production in 75 to 80 percent of men with congenital hypogonadotropic hypogonadism, although semen usually does not reach normal WHO parameters. There is still no clear consensus on which approach is best.256
Gonadorelin benefits for hypothalamic amenorrhea
In women, the classic use is hypothalamic amenorrhea, when periods stop because the brain’s GnRH signal falters while the ovaries stay healthy. A multicenter trial of Lutrepulse, intravenous pulsatile gonadorelin, enrolled 109 women. Ovulation occurred in 91 percent of those with primary and 96 percent of those with secondary hypothalamic amenorrhea.
The trial also reported the trade-offs. Complications from the intravenous line ranged from 0 to 11 percent, with a mean of 7 percent, multiple pregnancy occurred in 12 percent, and there was one case of ovarian hyperstimulation, in a woman who had also taken clomiphene. The author judged pulsatile GnRH at least as effective as injected gonadotropins, with lower overall risks.
A 2018 meta-analysis gathered 35 studies, three randomized and 32 observational, covering 1,002 women. It found high ovulation rates, a trend toward high pregnancy and live-birth rates, similar ovulation rates under the skin and into a vein, and ovarian hyperstimulation that was rare and mild. Multiple pregnancies were slightly more common than in the general population.
The rhythm story explains why it works so well here. The pituitary and ovaries are intact, and the pump simply restores the beat the hypothalamus stopped keeping. The likely reason singleton pregnancies dominate is that the body’s own feedback still governs how many follicles mature.34
Gonadorelin and testosterone therapy
A common question about gonadorelin today comes from men on testosterone therapy. The concern behind it is real. Prolonged testosterone therapy can suppress the hypothalamic-pituitary-testicular axis, lowering LH and FSH, reducing testosterone inside the testes, impairing sperm production, shrinking the testes and compromising fertility.
Current options include hCG, FSH and selective estrogen receptor modulators, with variable results. A 2026 narrative review of peptide and GnRH-based strategies concluded that they may support the body’s own hormone signaling, but that direct evidence of restored sperm production or fertility after testosterone suppression remains limited. Long-term effectiveness, safety, protocols and patient selection are unresolved.
There is also a physiological wrinkle, and it is a hypothesis worth naming. On testosterone therapy, the hypothalamus goes quiet because of feedback from the testosterone itself. Gonadorelin can stand in for that missing signal, but the 1978 monkey work suggests the pituitary responds best to a pulse and can tune out a steady supply. How well intermittent injections match that pattern has not been studied carefully in this setting.
None of that rules gonadorelin out. It means the decision belongs with a clinician who will check LH, FSH and testosterone, and a semen analysis if fertility is the goal, instead of with a protocol copied from a forum.71
What we know in people, and what we do not
By the standards of this guide, gonadorelin’s human record is deep. It includes a 1982 New England Journal of Medicine study, a 109-woman multicenter trial, a meta-analysis of more than a thousand women, and a body of specialist experience in congenital hypogonadotropic hypogonadism. For restoring a missing hypothalamic signal, the case is well made.
The limits are about where that evidence reaches. Only 3 of the 35 studies in the meta-analysis were randomized, the studies in men are small, and nearly all of the work used programmed pumps under specialist care. Very little of it speaks to occasional injections, to men on testosterone therapy, or to people whose hormone levels are normal to begin with.
The 2026 review of strategies for testosterone-therapy suppression reached the same conclusion from the other side. It called for well-designed clinical studies to establish long-term efficacy, safety and the role of these approaches before they can be considered settled.234657
Gonadorelin side effects and safety
In women, the main risks in trials were tied to the delivery method and to success itself. Intravenous lines brought line complications, and successful ovulation brought a modestly higher chance of twins or more. Ovarian hyperstimulation was rare and mild in the meta-analysis.
In men, skin reactions at the pump site were common in the 2019 study. As testosterone rises, men have reported breast tenderness, spontaneous erections and nocturnal emissions, which reflect the axis switching back on.
Delivery pattern matters. Constant exposure desensitizes the pituitary and lowers LH and FSH, the opposite of the usual goal. Long-term safety outside specialist pump programs has not been well documented.
People with hormone-sensitive cancers, anyone pregnant or breastfeeding, anyone with a pituitary condition, and men already using testosterone, clomiphene or hCG should talk with a clinician before considering it.34521
Labs that show whether gonadorelin makes sense
As a fertility treatment, pulsed gonadorelin fits mainly when the hypothalamus is the weak link and the pituitary and gonads can still respond, so the labs help find the weak link. LH and FSH are the pituitary’s outputs. In a man with low testosterone, low or normal LH and FSH point up the chain, toward the hypothalamus or pituitary. High LH and FSH point to the testes, where an extra GnRH signal would add little.
Total testosterone is the main downstream result in men. Estradiol tracks the ovarian axis in women, and in men much of it is made from androgens. In the 1982 pump study, gonadotropins reached the normal range within a week and testosterone rose within a month, so a retest shows whether the signal is landing.
Vitals Vault starts with this kind of panel. Blood is drawn at Quest Diagnostics, a licensed clinician reads the pattern alongside your history, and any decision about therapy comes with a plan to retest the same markers.2
Gonadorelin FDA status and sport
Gonadorelin has an unusual regulatory history. FDA approved Factrel, gonadorelin hydrochloride, on September 30, 1982, and Lutrepulse, gonadorelin acetate, an orphan drug, on October 10, 1989. Drugs@FDA lists both as discontinued, so no FDA-approved human gonadorelin product is marketed today.
It is not on FDA’s April 2026 compounding safety page, and it was not among the six peptides covered by FDA’s October 29, 2026 enforcement discretion. Ask the prescriber and pharmacist about its current compounding eligibility.
For athletes, the World Anti-Doping Agency’s 2026 Prohibited List names GnRH and gonadorelin under S2.2.1, testosterone-stimulating peptides prohibited in males, in and out of competition.1011131214
What this means for you
Gonadorelin is the body’s master reproductive signal, isolated from a quarter of a million pig brains and tested in people for more than four decades. Delivered in pulses, it restarted puberty, sperm production and ovulation in people whose hypothalamus had gone quiet. Delivered steadily, the same hormone family switches the axis off.
If you are wondering whether it fits you, start with where your axis is quiet. LH, FSH and testosterone or estradiol help a clinician tell a central signalling problem from a gland problem, and more testing may be needed to find the cause. If it is the signal, the next question worth asking is how any treatment plan will recreate a pulse.8241
What to expect with Gonadorelin
In pump studies, the axis woke up in a predictable order. LH and FSH reached the normal range within about a week, testosterone rose within a month, and sperm took many months to appear, a median of 6 months in one study and up to 43 weeks in the first. Ovulation in women with hypothalamic amenorrhea followed within treatment cycles.
For fertility goals, that means planning in months and measuring along the way, with LH, FSH and sex hormones early and semen analysis later. For questions about testosterone therapy, the evidence is thinner, so a clinician-led plan with labs before and after is the honest way to find out.2537
Key Gonadorelin studies
Belchetz et al., 19781
Animal study · Rhesus monkeys with hypothalamic lesions
Pulsed GnRH restored LH and FSH release; constant infusion failed and could desensitize
Limits: Monkeys, not people
Hoffman and Crowley, 19822
Long-term pump study · 6 men with idiopathic hypogonadotropic hypogonadism
Testosterone rose from 77 to 520 ng/dL in a month; 3 made sperm by 43 weeks
Limits: Very small; no control group
Santoro, 1990 (Lutrepulse)3
Multicenter trial · 109 women with hypothalamic amenorrhea
Ovulation in 91% (primary) and 96% (secondary)
Limits: Intravenous pump; 12% multiple pregnancy
Tranoulis et al., 20184
Systematic review and meta-analysis · 1,002 women across 35 studies
High ovulation rates; low, mild hyperstimulation; mostly singleton pregnancies
Limits: Only 3 of 35 studies randomized
Zhang et al., 20195
Nonrandomized comparison · 28 men with congenital hypogonadotropic hypogonadism
Sperm at a median 6 months on the pump versus 14 on gonadotropins
Limits: Not randomized; small
Dwyer et al., 20246
Review · Men with congenital hypogonadotropic hypogonadism
Pulsatile GnRH or gonadotropins induce sperm in 75 to 80%
Limits: No consensus on the best approach
Cretu et al., 20267
Narrative review · Men with testosterone-therapy suppression
Peptide and GnRH approaches may support natural signaling
Limits: Direct fertility evidence after suppression remains limited
Gonadorelin myths and evidence
More gonadorelin means more testosterone
Pattern beats amount. In monkeys, pulsed GnRH restored LH and FSH, while constant exposure failed and could desensitize the pituitary. Steady GnRH-type signals are how prostate cancer drugs lower testosterone.18
Gonadorelin and hCG do the same job
They act at different levels. Gonadorelin prompts the pituitary to release the body’s own LH and FSH. hCG acts directly on the testes like LH. In one study, a gonadorelin pump produced sperm sooner than cyclical hCG and hMG.5
Gonadorelin is proven to protect fertility on testosterone therapy
Not yet. A 2026 review found direct evidence of restored sperm production or fertility after testosterone suppression remains limited, with protocols and long-term safety unresolved.7
Gonadorelin is a new research peptide
Its structure was published in 1971, it was tested in men in 1982, and FDA approved two gonadorelin drugs in 1982 and 1989 before both were discontinued.921011
How is Gonadorelin taken?
Gonadorelin dosage
The two FDA-approved human gonadorelin products, Factrel and Lutrepulse, are listed as discontinued in Drugs@FDA, and their labels are not posted on those pages. The table shows a published human-study regimen instead: in a male fertility trial, a programmed pump gave small pulses under the skin every 90 minutes, adjusted to LH, FSH and testosterone. Any dosing chart should name its human source, population, route and schedule. Your clinician sets any dose.51011
Typical Gonadorelin dosage
Factrel and Lutrepulse, the two FDA-approved human gonadorelin products, are listed as discontinued in Drugs@FDA, and their labels are not posted there. The table shows a published human trial in men with congenital hypogonadotropic hypogonadism: small pulses under the skin from a programmed pump every 90 minutes, adjusted to LH, FSH and testosterone. A clinician decides whether any use fits you.
Already have a prescribed dose? The peptide dosage calculator turns it into the units to draw on an insulin syringe.
Human trial · Pulses under the skin of the abdomen from a programmed infusion pump
10 µg per pulse to start (raised to 15 µg in one man, lowered to 3 µg in another)
Every 90 minutes5
Azoospermic men with congenital hypogonadotropic hypogonadism, to start sperm production; adjusted to LH, FSH and testosterone; follow-up up to 24 months (full-text methods).
Is Gonadorelin right for you?
A clinician makes the call. These are the questions they will ask first.
It may suit
- Adults with a diagnosed hypothalamic cause of low testosterone, absent periods or infertility, managed by an endocrinologist
- People who want LH, FSH, testosterone and estradiol tracked to see which link is under-performing
Talk to a clinician first if you are
- Hormone-sensitive cancers (prostate or breast)
- Planning pregnancy, pregnant or breastfeeding
- Tested athletes (WADA prohibits gonadorelin in males)
- Currently using testosterone, clomiphene or hCG
- A pituitary condition or a history of allergic skin reactions to injections
Vitals Vault peptide care starts with a blood panel and a licensed clinician, and ends with a retest.
Get early access to peptide careFertility hormones run on rhythm, not just on amount
Gonadorelin is useful for hypothalamic failure, not as a general testosterone booster. If the brain’s signal is the weak link, a pulse fixes it. If the pituitary or testes are the weak link, it does not.
So the first job is working out which link is weak, and whether something, such as testosterone therapy, is suppressing the signal.127
What else moves the same system
- 01Find the weak linkIf the pituitary or testes cannot respond, even a perfect pulse gets no answer.
- 02Check what suppresses the axisTestosterone therapy suppresses LH and FSH, and a 2026 review found direct evidence for restoring fertility afterward is limited.
- 03Keep the rhythmA single occasional injection does not copy the timed pump used in trials.
- 04Measure the chainLH, FSH, total testosterone and estradiol show where the axis is under-performing.
Labs to check with Gonadorelin
A blood test before you start and a retest after shows what actually changed for you. It is how Vitals Vault approaches every treatment.
- TestA baseline panel at Quest Diagnostics.
- DecideA licensed clinician reviews your history and results.
- RetestThe same markers again, side by side.
- LHThe pituitary hormone gonadorelin drives. Low or normal LH with low testosterone points to the hypothalamus or pituitary.
- FSHPairs with LH and tracks sperm production and ovarian response.
- Total testosteroneThe main downstream result of the axis in men.
- EstradiolTracks the ovarian axis in women and aromatised testosterone in men.
Is Gonadorelin FDA approved?
Not today. FDA approved two human gonadorelin drugs, Factrel (gonadorelin hydrochloride) on September 30, 1982, and Lutrepulse (gonadorelin acetate, an orphan drug) on October 10, 1989. Drugs@FDA lists both as discontinued, and no human gonadorelin product is currently marketed. Gonadorelin is not on FDA’s April 2026 compounding safety page, and it was not among the six peptides covered by FDA’s October 29, 2026 enforcement discretion.10111312
Gonadorelin timeline
1978
Monkey study shows pulsed GnRH restores gonadotropin release while constant infusion fails and can desensitise.1
September 30, 1982
FDA approves Factrel (gonadorelin hydrochloride).10
1982
Pulsed GnRH induces puberty and sperm production in men with idiopathic hypogonadotropic hypogonadism.2
October 10, 1989
FDA approves Lutrepulse (gonadorelin acetate), an orphan drug.11
1990
Multicentre trial shows pulsatile gonadorelin triggers ovulation in women with hypothalamic amenorrhea.3
2018
Meta-analysis of 35 studies finds pulsatile GnRH effective and safe in hypothalamic amenorrhea.4
2026
WADA’s Prohibited List names GnRH and gonadorelin among testosterone-stimulating peptides in males.14
Gonadorelin questions
What is gonadorelin?
Gonadorelin is the synthetic form of GnRH, the hypothalamic hormone that makes the pituitary release LH and FSH. It was approved by FDA as Factrel in 1982 and Lutrepulse in 1989. Both are now discontinued.
What is gonadorelin used for?
In trials, pulsed gonadorelin was used to restore puberty and sperm production in men with hypogonadotropic hypogonadism and to induce ovulation in women with hypothalamic amenorrhea. It is not FDA-approved for any use today.
What are the benefits of gonadorelin?
Pulsatile gonadorelin raised testosterone and produced sperm in men with hypothalamic failure, and triggered ovulation in over 90 percent of women with hypothalamic amenorrhea in one trial. These results apply to pump delivery under specialist care.
How does gonadorelin work?
It acts on the pituitary like natural GnRH, prompting LH and FSH release. The pattern matters, since pulses restore the axis and constant exposure desensitises it.
What are the side effects of gonadorelin?
Reported effects include skin reactions with the pump, intravenous line complications, multiple pregnancy and, rarely, ovarian hyperstimulation in women. In men, breast tenderness and erections have been reported with gonadotropin rise.
What is the gonadorelin dosage?
Factrel and Lutrepulse, the FDA-approved human products, are listed as discontinued in Drugs@FDA, and their labels are not posted there. The table on this page shows a published human regimen: in a male fertility trial, a programmed pump gave small pulses every 90 minutes, adjusted to LH, FSH and testosterone. Your clinician sets any dose.
Gonadorelin vs hCG, what is the difference?
Gonadorelin acts on the pituitary, so the body then makes its own LH and FSH. hCG acts directly on the testes like LH. In one study of men with congenital hypogonadotropic hypogonadism, a gonadorelin pump produced sperm earlier than cyclical hCG-based or hMG-based therapy.
Is gonadorelin used with testosterone therapy?
People ask about it to limit testicular shrinkage on testosterone. A 2026 review found direct evidence for restoring sperm production after testosterone-induced suppression remains limited, so it is a conversation for your clinician.
Is gonadorelin FDA approved or legal?
FDA approved Factrel in 1982 and Lutrepulse in 1989, and both are discontinued, so no human product is marketed. It is not on FDA’s compounding safety page and was not covered by the October 2026 enforcement discretion, so ask your prescriber and pharmacist about eligibility.
Is gonadorelin banned in sports?
In males, yes. WADA’s 2026 Prohibited List names GnRH and gonadorelin among testosterone-stimulating peptides, prohibited in and out of competition.
Can I get gonadorelin through Vitals Vault?
Vitals Vault is opening clinician-led peptide care that starts with a blood test, and you can join the peptides waitlist to hear first. A licensed clinician reviews your history and labs and decides whether gonadorelin is right for you.
Peptides, prescribed and measured
Vitals Vault is opening peptide care that starts with your blood work, is prescribed by licensed US clinicians and ends with a retest. Join the waitlist to hear first.
- Prescription only
- Licensed US clinicians
- Quest Diagnostics labs
Keep reading
Full Peptide Guide- Kisspeptin-10The shortest active piece of kisspeptin, the brain signal that switches on the reproductive hormone axis.
- PT-141Bremelanotide, an FDA-approved melanocortin peptide for low sexual desire in premenopausal women, sold as Vyleesi.
- TesamorelinAn FDA-approved growth hormone releasing factor analog (Egrifta) for excess abdominal fat in adults with HIV-associated lipodystrophy.
- FDA peptide update 2026What FDA’s October 2026 decision on six peptides means for you.
Sources
- 1. Belchetz PE, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978 (opens in a new tab)
- 2. Hoffman AR, et al. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982 (opens in a new tab)
- 3. Santoro N, et al. Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. Am J Obstet Gynecol. 1990 (opens in a new tab)
- 4. Tranoulis A, et al. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. Fertil Steril. 2018 (opens in a new tab)
- 5. Zhang L, et al. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. Am J Mens Health. 2019 (opens in a new tab)
- 6. Dwyer AA, et al. Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism. Ann N Y Acad Sci. 2024 (opens in a new tab)
- 7. Cretu AM, et al. Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review. Front Reprod Health. 2026 (opens in a new tab)
- 8. Benisti S, et al. Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation. JNCI Cancer Spectr. 2026 (opens in a new tab)
- 9. Matsuo H, et al. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971 (opens in a new tab)
- 10. Drugs@FDA. Factrel (gonadorelin hydrochloride), NDA 018123, approved September 30, 1982, now discontinued (opens in a new tab)
- 11. Drugs@FDA. Lutrepulse (gonadorelin acetate), NDA 019687, approved October 10, 1989, now discontinued (opens in a new tab)
- 12. NCPA. FDA grants enforcement discretion for compounding six peptides. October 29, 2026 (opens in a new tab)
- 13. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of April 22, 2026) (opens in a new tab)
- 14. World Anti-Doping Agency. 2026 Prohibited List (S2.2.1 testosterone-stimulating peptides in males) (opens in a new tab)